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OBJECTIVE—Obesity is characterized by elevated levels of
proinﬂammatory cytokines, including interleukin (IL)-1b, that
contribute to the development of insulin resistance. In this study,
we set out to investigate whether hyperglycemia drives IL-1b
production and caspase-1 activation in murine and human adi-
pose tissue, thus inducing insulin resistance.
RESEARCH DESIGN AND METHODS—ob/ob animals were
used as a model to study obesity and hyperglycemia. Human
adipose tissue fragments or adipocytes were cultured in medium
containing normal or high glucose levels. Additionally, the role of
thioredoxin interacting protein (TXNIP) in glucose-induced IL-1b
production was assessed.
RESULTS—TXNIP and caspase-1 protein levels were more
abundantly expressed in adipose tissue of hyperglycemic ob/ob
animals as compared with wild-type mice. In human adipose tis-
sue, high glucose resulted in a 10-fold upregulation of TXNIP
gene expression levels (P , 0.01) and a 10% elevation of cas-
pase-1 activity (P , 0.05), together with induction of IL-1b tran-
scription (twofold, P , 0.01) and a signiﬁcant increase in IL-1b
secretion. TXNIP suppression in human adipocytes, either by a
small interfering RNA approach or a peroxisome proliferator–
activated receptor-g agonist, counteracted the effects of high glu-
cose on bioactive IL-1 production (P , 0.01) mainly through a
decrease in transcription levels paralleled by reduced intracellu-
lar pro-IL-1b levels.
CONCLUSIONS—High glucose activates caspase-1 in human and
murine adipose tissue. Glucose-induced activation of TXNIP medi-
ates IL-1b mRNA expression levels and intracellular pro-IL-1b accu-
mulation in adipose tissue. The concerted actions lead to enhanced
secretion of IL-1b in adipose tissue that may contribute to the de-
velopment of insulin resistance. Diabetes 60:517–524, 2011
O
besity is associated with a low-grade systemic
inﬂammation, with elevated levels of proin-
ﬂammatory cytokines, such as interleukin (IL)-
1b, tumor necrosis factor-a (TNF-a), and IL-6,
that contribute to the development of insulin resistance
and progression to type 2 diabetes mellitus (1,2). The
mechanisms that trigger the development of inﬂammation
are currently unknown, although the adipose tissue has
been viewed upon as the instigator of these effects (3,4).
Earlier studies have shown that high glucose promotes the
production of acute phase reactants (5) and proinﬂam-
matory cytokines by adipocytes (6). In addition, several
studies have shown that hyperglycemia induces the pro-
duction of IL-1b in different cell types including endothe-
lial cells, monocytes, b-cells, and other pancreatic islet
cells (7–9). Although short time exposure to low concen-
trations of IL-1b enhances b-cell function, high glucose-
induced islet IL-1b secretion is known to negatively in-
terfere with insulin signaling and has cytotoxic effects on
b-cells leading to impaired insulin secretion (8,10). IL-1b is
produced via cleavage of pro-IL-1b by caspase-1, a cyste-
ine protease (11) that is activated by a protein complex
named the inﬂammasome (12). Until recently, the mecha-
nism by which high glucose induces IL-1b remained largely
unknown. However, in a recent study Zhou et al. demon-
strated a crucial role for thioredoxin interacting protein
(TXNIP or vitamin D3 upregulated protein 1 [VDUP1])
during high glucose-mediated caspase-1 activation in
murine b-cells, by direct interaction with the nucleotide-
binding oligomerization domain (NOD)-like receptor
(NLR)-3 (NLRP3)-inﬂammasome (13). TXNIP is expressed
in a wide variety of cell types including skeletal myocytes,
pancreatic b-cells, endothelial cells, and adipocytes and
acts as an endogenous inhibitor of the reactive oxygen
species (ROS) scavenging protein thioredoxin (14,15).
TXNIP levels are elevated in subjects with type 2 diabetes
mellitus (15), and its expression is induced by glucose-
6-phosphate through an intracellular transcriptional com-
plex of MondoA and Max-like protein X (16).
Here we investigate whether high glucose levels also
drive TXNIP and caspase-1 activation in human adipocytes
and intact adipose tissue and whether this may contribute
to the production of IL-1b.
RESEARCH DESIGN AND METHODS
Animal experiments. Blood glucose levels of ﬁve 8-week-old male ob/ob C57/
Bl6 and wild-type C57/Bl6 animals (Jackson Laboratory) were determined
after 4 h of fasting. A glucose tolerance test and insulin tolerance test were
performed in ﬁve 8-week-old male caspase-1
2/2 C57/Bl6 mice (average body
wt: 23.6 g) and ﬁve age- and weight-matched wild-type C57/Bl6 animals. Epi-
didymal white adipose tissue was used to analyze protein levels of caspase-1
and TXNIP.
In vitro and ex vivo experiments with human adipose tissue. Intact ad-
ipose tissue fragments and cultured human preadipocytes from subcutaneous
adipose tissue (n=6), obtained during plastic surgery, and the SGBS cell line
were used to study the effects of high glucose levels. The protocol was ap-
proved by the hospital ethics committee, and the tissue samples were col-
lected after written informed consent. Adipose tissue fragments were directly
cultured for 48 h in Dulbecco’s modiﬁed Eagle’s medium supplemented with
10% fetal calf serum containing normal glucose levels (5 mM) or high glucose
levels (25 mM). Preadipocytes were isolated from the adipose tissue according
to the procedure described by Rodbell (17). Primary or SGBS preadipocytes
were differentiated toward mature adipocytes using a standard adipogenic
protocol (18). After 12 days of differentiation adipocytes were cultured under
5 or 25 mM glucose conditions. Mannose was added to cells cultured in the
presence of 5 mM glucose.
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BRIEF REPORTRNA isolation and PCR analysis. RNA was extracted from total adipose
tissue or adipocytes using TRIzol reagent (Invitrogen, Carlsbad, CA). cDNA
synthesis was performed using the iScript cDNA Synthesis Kit (Bio–Rad
Laboratories, Hercules, CA). Real-time PCR was done using Power-SYBR
Green master mix and the 7300 Real-Time PCR system (Applied Biosystem,
Warrington, U.K.). Expression of genes was normalized to b22M or 36B4 gene
expression levels. Primer sequences are available upon request.
Protein analysis. Protein expression of TXNIP, caspase-1, b-actin, and
GAPDH were measured by Western blotting. Antibodies were from Santa Cruz
(caspase-1), Zymed (TXNIP), Abcam (NLRP3), Sigma-Aldrich (b-actin), and
Calbiochem (GAPDH). Bioactive IL-1 secretion was quantiﬁed in a bioassay
using the murine thymoma cell line EL4/NOB 1 that produces IL-2 in response
to bioactive IL-1 (19). IL-2 and intracellular human pro-IL-1b levels were
measured by Elisa (R&D). In short, medium collected from adipocytes or total
adipose tissue cultured in the presence of 5 or 25 mM of glucose was added to
NOB-1 cells. After 24 h of incubation, medium was used for IL-2 measure-
ments. The speciﬁcity of the NOB-1 assay to produce IL-2 in response to IL-1b
was conﬁrmed in this study (Supplementary Fig. 1).
Caspase-1 activity assay. Caspase-1 activity in adipocyte lysates was de-
termined with acaspase-1 ﬂuorometrickit (Biovision) following thecleavage of
50 mmol/L peptide YVAD-AFC. The ﬂuorescence of the cleaved substrate was
measured every 90 s using a ﬂuorometer (Polarstar BMG, ﬂuostar galaxy).
Small interfering RNA. To speciﬁcally suppress TXNIP expression in differ-
entiated adipocytes, cells were transfected (X-tremeGENE siRNA Transfection
Reagent, Roche) with small interfering (si)RNA against TXNIP (Thermo Scien-
tiﬁc). As a nonspeciﬁc control, scrambled siRNA (Thermo Scientiﬁc) was used.
Statistical analysis. Variables are expressed as means 6 SD. One-way
ANOVA, the Wilcoxon rank test, and Student paired t test were used to analyze
statistical signiﬁcance. Two-tailed P , 0.05 was considered signiﬁcant. All
statistical analyses were performed using SPSS software (version 16.0; SPSS,
Chicago, IL).
RESULTS
To determine whether hyperglycemic conditions induce
caspase-1 and TXNIP in adipose tissue in vivo, we used the
ob/ob animal model, which is characterized by obesity,
insulin resistance, and hyperglycemia (Fig. 1A). Both the
inactive procaspase-1 (p45) and the active caspase-1 (p35)
protein levels were upregulated in ob/ob mice compared
with the normoglycemic wild-type animals (Fig. 1B). In
parallel with caspase-1 activation, TXNIP protein levels
were elevated in adipose tissue of ob/ob animals. Inter-
estingly, the absence of caspase-1 led to an improvement
of glucose tolerance (Fig. 1C) and insulin sensitivity (Fig.
1D). Supported by the observation that TXNIP
2/2 animals
FIG. 1. TXNIP and caspase-1 protein levels are increased in the adipose tissue of ob/ob mice. A: Plasma glucose levels in fasted wild-type mice and
ob/ob mice (n=5 per group). B: Western blot images and quantiﬁcation of TXNIP, procaspase-1 (p45), and active caspase-1 (p35) protein levels in
the epididymal adipose tissue of wild-type mice and ob/ob mice (n=5 per group). C: A glucose tolerance test was done using fasted wild-type and
caspase-1
2/2 animals (n=5 animals per group). D: An insulin tolerance test was performed in fasted wild-type and caspase-1
2/2 animals (n=5
animals per group). *P < 0.05; **P < 0.01 using a Student t test.
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518 DIABETES, VOL. 60, FEBRUARY 2011 diabetes.diabetesjournals.orgFIG. 2. Hyperglycemia induces proinﬂammatory gene expression and results in an increased production of IL-1 by intact adipose tissue and
adipocytes. A: IL-6, IL-8,a n dPPAR-g gene expression levels in human intact adipose tissue (n=3) after 6 or 48 h of glucose treatment. B: IL-1b
gene expression levels in human adipose tissue (n=3) treated with glucose for 6 or 48 h. C: IL-1b and IL-18 gene expression levels in human
primary adipocytes (n=3) treated with various concentrations of glucose. D and E: Intracellular pro-IL-1b levels measured in lysates from intact
human adipose tissue (D) or human primary adipocytes (E) treated with 5 or 25 mM glucose for 48 h (n=4) and IL-2 production from NOB-1 cells
T.B. KOENEN AND ASSOCIATES
diabetes.diabetesjournals.org DIABETES, VOL. 60, FEBRUARY 2011 519are more insulin sensitive (20), these in vivo results
strongly suggest a link between TXNIP and caspase-1 ac-
tivation during hyperglycemic conditions in adipose tissue
that contributes to the development of insulin resistance.
We next studied the effects of high glucose on caspase-1
activation and the production of IL-1b in human adipose
tissue. Treatment of adipose tissue with 25 mM glucose
increased the gene expression levels of proinﬂammatory
mediators including IL-6 and IL-8 (P , 0.01) together with
a signiﬁcant fourfold reduction in PPAR-g expression
levels (Fig. 2A). Moreover, IL-1b gene expression levels
were also elevated upon short- or long-term stimulation of
adipose tissue and adipocytes with 25 mM of glucose (7.5-
fold, P , 0.01; fourfold, P , 0.06, respectively), whereas
IL-18 levels were unaffected (Fig. 2B and C). In line with
activation of IL-1b transcription levels, both the in-
tracellular content of pro-IL-1b and secretion of bioactive
IL-1 were signiﬁcantly elevated after exposure of adipo-
cytes or intact adipose tissue to 25 mM of glucose (Fig. 2D
and E). Because IL-1 production depends on caspase-1
activation, we determined caspase-1 activity levels in adi-
pocytes treated with 5 or 25 mM of glucose. As shown in
Fig. 2F, a signiﬁcant increase in caspase-1 activity was
observed in primary human adipocytes treated with 25 mM
of glucose for 48 h, compared with adipocytes treated with
5 mM of glucose. In line with the enhanced caspase-1 ac-
tivity, high glucose levels led to an increase in NLRP3
protein levels in primary human adipocytes (Fig. 2G). Al-
though only a trend was observed (P = 0.07), our results
imply that NLRP3 is one of the signaling molecules that
translate high glucose levels into caspase-1 activation.
Noticeably, similar results were obtained using human
adipose tissue explants (data not shown). Overall, these
results suggest that high glucose induces IL-1b transcrip-
tion, activation of caspase-1, and secretion of IL-1 in hu-
man adipose tissue.
To assess whether high glucose induces TXNIP in hu-
man adipose tissue and adipocytes to a similar extent as
observed in ob/ob animals, we ﬁrst studied the regulation
of TXNIP during the differentiation of human preadipo-
cytes toward fully mature adipocytes. Whereas TXNIP is
expressed in human preadipocytes, expression levels rap-
idly increased during differentiation toward mature adipo-
cytes both at gene and protein expression levels (Fig. 3A).
In addition to caspase-1, TXNIP protein levels were de-
tectable in total human subcutaneous adipose tissue and
tended to increase in parallel with BMI (Fig. 3B). Because
adipose tissue is composed of both adipocytes and non-
adipocyte cells, including inﬂammatory cells, we deter-
mined gene expression levels in both fractions. Purity of
the different fractions was conﬁrmed with the markers
adiponectin (adipocyte-speciﬁc) and F4/80+ (macrophage-
speciﬁc) (Supplementary Fig. 2). Whereas TXNIP is
expressed in the stromal vascular fraction (SVF), expression
levels were 2.5 times higher in adipocytes (Fig. 3C). As
shown in Fig. 3D and E, glucose was a potent regulator of
TXNIP mRNA expression in both isolated adipocytes and
adipose tissue explants. Furthermore, treatment of adipo-
cytes with 5 mM 2-deoxyglucose leading to a chronic
activation of the MondoA:Mlx, resulted in a more pro-
nounced activation of TXNIP gene expression (Fig. 3D
and E). In line with these transcriptional changes, pro-
tein levels of TXNIP varied in response to different
glucose concentrations added to adipocytes or intact
a d i p o s et i s s u e( F i g .3 F and G).
Because high glucose potently activates TXNIP expres-
sion in adipocytes (Fig. 3) and TXNIP has been shown to
induce IL-1b secretion from mouse pancreatic islets cells
in response to elevated glucose via activation of caspase-1
(13), we investigated whether TXNIP mediates high glu-
cose-induced IL-1 production in human adipocytes using
siRNA targeted against TXNIP. In adipocytes exposed to
25 mM of glucose, successful knockdown of TXNIP by
siRNA (Fig. 4A) led to a signiﬁcant reduction in bioactive
IL-1 production toward basal IL-1 levels induced by 5 mM
glucose (Fig. 4B). Additionally, IL-1b transcription and
intracellular levels of pro-IL-1b were reduced upon siRNA-
mediated depletion of TXNIP (Fig. 4C). Whereas high
glucose treatment increased caspase-1 activity levels in
adipocytes (Fig. 2F), siRNA-mediated knockdown of TXNIP
had no effect on caspase-1 activation (Fig. 4D). Interest-
ingly, reducing TXNIP gene expression with the PPAR-g
agonist Rosiglitazone in adipocytes and adipose tissue
explants exposed to 25 mM glucose for 48 h (Fig. 4E) also
led to a signiﬁcant decrease in intracellular pro-IL-1b and
bioactive IL-1 production (Fig. 4F and G). These results
demonstrate that TXNIP contributes to high glucose-in-
duced IL-1 release by modulating the transcription of IL-
1b and the intracellular pool of pro-IL-1b.
DISCUSSION
Several studies show that IL-1b deteriorates peripheral
insulin sensitivity and inhibits insulin production by the
pancreas (8,10). The notion that IL-1b is relevant in human
(patho)physiology is supported by the ﬁnding that block-
ing of IL-1 signaling pathways in type 2 diabetes melli-
tus patients by treatment with IL-1 receptor antagonist
Anakinra improves glycemic control (21). However, the
precise mechanisms leading to an enhanced production of
IL-1b in the inﬂamed adipose tissue over the course of
development of insulin resistance have remained obscure.
The importance of hyperglycemia-induced insulin resis-
tance in type 2 diabetes mellitus patients is well accepted,
although no current explanation is available for this pro-
cess. The stimulatory role of hyperglycemia on IL-1b pro-
duction has been, however, known for several years (7–9).
The combination of this knowledge with the recent dis-
covery of the important effect of IL-1b on the induction
of insulin resistance (22) directed us to the hypothesis
that hyperglycemia induces insulin resistance in adipose
tissue through activation of caspase-1 and IL-1b secretion.
Moreover, Zhou et al. have recently uncovered TXNIP as
an essential mediator of hyperglycemia-induced caspase-
1-dependent IL-1b production in the murine pancreatic
b-cell (13), and we explored whether TXNIP could mediate
a similar effect in human and murine adipocytes. Our data
clearly show that adipose tissue-resident caspase-1 and
after exposure to medium from intact human subcutaneous adipose tissue of three different donors treated with 5 or 25 mM of glucose for 48 h.
F: Caspase-1 activity assay in primary human adipocytes treated with 5 mM, 25 mM of glucose, or LPS (10 ng/mL) for 48 h. The left graph displays
the results of one representative experiment. The right graph displays the average results of n=6 experiments. G: NLRP3 protein expression
levels in human primary adipocytes treated with 5 or 25 mM of glucose for 48 h. A representative Western blot and quantiﬁcation of the results (n=3)
are shown. *P < 0.05; **P value < 0.01 using a one-way ANOVA test (A–C), Student t test (D and E), or a Wilcoxon rank test (F; right graph).
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520 DIABETES, VOL. 60, FEBRUARY 2011 diabetes.diabetesjournals.orgFIG. 3. TXNIP is present in human adipose tissue and adipocytes and is regulated by glucose. A: TXNIP gene and protein expression levels during
adipocyte differentiation of human primary adipocytes or human SGBS adipocytes. B: Western blot images of caspase-1 and TXNIP protein levels
in total human subcutaneous adipose tissue (n=2). C: Relative gene expression levels of TXNIP in mature adipocytes or the SVF isolated from
human adipose tissue (n=3). D: Gene expression levels of TXNIP in intact adipose tissue treated with various concentrations of glucose (n=3).
E: Gene expression levels of TXNIP in human primary adipocytes treated with various concentrations of glucose (n=3). F: Protein levels of TXNIP
in human adipose tissue after 5 mM glucose, 25 mM glucose, or 5 mM deoxyglucose treatment for 48 h (n=2). G: Protein levels of TXNIP after
glucose starvation (no glucose), 5 mM glucose, and 25 mM glucose for 48 h in human primary adipocytes. *P < 0.05; **P < 0.01 using a one-way
ANOVA test (D and E) or a Student t test (C).
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and in human adipose tissue treated with 25 mM of glu-
cose, resulting in an increased IL-1b production. Both the
absence of caspase-1 and TXNIP (20) signiﬁcantly im-
proved insulin sensitivity and resulted in lower plasma
glucose levels. Together, these ﬁndings strengthen the con-
cept that aberrant IL-1b production via caspase-1 underlies
the pathophysiology of type 2 diabetes mellitus in different
cellular sources, linking this disease to auto-inﬂammatory
syndromes.
The glucose-responsive TXNIP gene has been previously
linked to diabetes and insulin resistance, because diabetic
patients expressed consistently higher TXNIP mRNA gene
levels in skeletal muscles (15), whereas animals lacking
TXNIP displayed a hypoglycemic, hypoinsulinemic phe-
notype (23). Furthermore, it has been shown that PPAR-g
negatively regulates TXNIP expression in adipose tissue
(24). In agreement, we showed that activation of PPAR-g
by its agonist Rosiglitazone led to reduced TXNIP levels
together with a decline in IL-1b. The elucidation of the
exact molecular mechanisms through which TXNIP con-
tributes to enhanced IL-1b production by the adipose tis-
sue will need further study. Whereas TXNIP has been
shown to directly control caspase-1 activation in pancreatic
b-cells (13), our results suggest that, at least in adipocytes,
TXNIP mainly regulates IL-1b mRNA transcription levels
and intracellular pro-IL-1b pools and does not directly af-
fect caspase-1 activity levels. This discrepancy may largely
be explained by cell-speciﬁc differences in adipocytes
versus pancreatic b-cells. In line with our results, Masters
et al. reported no changes in caspase-1 activation upon
TXNIP depletion in macrophages. However, these authors
also failed to detect differences in IL-1b production upon
stimulation with ATP and uric crystals in wild-type versus
TXNIP
2/2 macrophages (25). This could be explained by
the constitutive large expression of TXNIP in macrophages
that is not inﬂuenced by high levels of glucose. In contrast,
TXNIP does play a role in adipocyte glucose homeostasis
and elevated levels of glucose potently induce TXNIP ex-
pression in adipocytes (15).
Because excessive production of ROS has been found to
increase IL-b activity and may contribute to the toxic ef-
fect of high glucose on b-cells (26), future studies will need
to reveal a possible role of TXNIP-induced oxidative stress
induced by high glucose in mediating the release of IL-1b
by adipose tissue. In addition, it would be interesting to
investigate whether other metabolic stress signals that are
elevated during the development of insulin resistance bear
the potential to induce caspase-1.
In conclusion, adipocyte-speciﬁc TXNIP upregulation
induced by hyperglycemia may contribute to a sustained
proinﬂammatory state and hyperglycemia-associated in-
sulin resistance partly through inducing IL-1b transcrip-
tion. Furthermore, elevated levels of glucose increased the
activation of caspase-1 in adipocytes. Although more
efforts are needed, the high glucose-induced increase in
NLRP3 protein levels in primary human adipocytes sug-
gests involvement of the NLRP3-inﬂammasome in medi-
ating caspase-1 activation during hyperglycemic conditions.
Therefore, we suggest that, at least in adipose tissue, both
activation of TXNIP and caspase-1 during hyperglycemic
conditions lead to an enhanced production of IL-1b (Fig. 4H).
In this way, TXNIP links hyperglycemia to increased IL-1b
production that may result in insulin resistance at the level
of the adipose tissue. As a consequence, inhibition of TXNIP
may represent a novel therapeutic target in the treatment
of insulin resistance that will ameliorate adipose tissue
functioning.
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